This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally

Vestal Point Capital sold 1,054,000 Nuvalent shares in the fourth quarter, an estimated $103.93 million trade based on quarterly average pricing. The fund's quarter-end Nuvalent position value declined by $90.50 million, reflecting both trading activity and stock price movement.